IQVIA Holdings Inc. $IQV Shares Sold by Lynwood Price Capital Management LP

Lynwood Price Capital Management LP lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 47.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 28,000 shares of the medical research company’s stock after selling 25,079 shares during the quarter. IQVIA comprises about 2.7% of Lynwood Price Capital Management LP’s portfolio, making the stock its 11th largest position. Lynwood Price Capital Management LP’s holdings in IQVIA were worth $5,318,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Boston Partners acquired a new stake in shares of IQVIA during the third quarter worth about $676,698,000. Artisan Partners Limited Partnership purchased a new position in IQVIA during the 2nd quarter worth approximately $515,772,000. Norges Bank acquired a new stake in IQVIA during the 2nd quarter valued at approximately $270,160,000. AQR Capital Management LLC boosted its holdings in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Finally, Laurel Wealth Advisors LLC increased its stake in shares of IQVIA by 15,755.2% in the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $167.28 on Thursday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a market capitalization of $28.39 billion, a PE ratio of 21.28, a P/E/G ratio of 1.63 and a beta of 1.39. The business’s 50 day moving average price is $197.21 and its 200-day moving average price is $206.33.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter last year, the firm posted $3.12 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IQV shares. Evercore restated an “outperform” rating and set a $225.00 target price on shares of IQVIA in a research report on Thursday, February 5th. UBS Group reduced their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Finally, Jefferies Financial Group decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and a consensus target price of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.